Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01059227 · ClinicalTrials.gov registry record
Effects of a CRF1 Receptor Antagonist on Human Startle in Normal Female Volunteers
A clinical trial, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- 39
- Enrollment target
NCT01059227: Completed study, sponsored by National Institute of Mental Health (NIMH).
NCT01059227 is a clinical trial that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01059227 has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- 39 participants
- Enrollment target
Study Summary
Background: \- Research has shown that the hormone corticotropin-releasing hormone (CRH) is involved in stress and anxiety, and that drugs that block the effect of CRH in the body can reduce anxiety. GSK561679 is an experimental drug that attempts to reduce anxiety by blocking the effect of CRH. Researchers are interested in comparing GSK561679 with other treatments for anxiety. Objectives: \- To determine the effectiveness of GSK561679 compared with placebo and alprazolam (Xanax), as a possible treatment for fear and anxiety. Eligibility: \- Healthy female volunteers between 21 and 50 years of age. Design: * This study will involve one screening visit, four testing visits, and one follow-up visit over a period of 8-9 weeks. The testing sessions will be between 6-11 days apart. * Participants must follow these dietary restrictions to participate in the study. * No nicotine, alcohol, or caffeine (including chocolate and soft drinks) for 24 hours before the start of the study. * No nicotine in the past 6 months, and no nicotine until the final blood sample is collected at the follow-up visit. * No alcohol or caffeine for 24 hours before a testing visit or for 72 hours after each visit. * No grapefruit or grapefruit products from 14 days before the first dose of study medication until collection of the final blood sample. * Participants will receive a dose of GSK561679, alprazolam, or placebo 3 hours before the testing, and will take an additional pill 1 hour before the testing. * During the tests, participants will receive brief electric shocks and hear sudden loud noises. The noises and shocks will be given over a period of approximately 40 minutes per session. * Skin conduction, heart rate, and blinking will be monitored throughout the tests, and participants will be asked about anxiety levels and will be tested on mood, memory, and concentration. Blood and saliva samples will also be taken during these sessions. * Participants will stay in the clinical cente
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2010-01-22 |
| Est. Completion | 2015-08-14 |
What the finished NCT01059227 record still lists
NCT01059227 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 39 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01059227 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01059227 about?
NCT01059227 is a clinical study titled "Effects of a CRF1 Receptor Antagonist on Human Startle in Normal Female Volunteers". Background: \- Research has shown that the hormone corticotropin-releasing hormone (CRH) is involved in stress and anxiety, and that drugs that block the effect of CRH in the body can reduce anxiety. GSK561679 is an experimental drug that attempts to reduce anxiety by blocking the effect of CRH. Re...
What is the current status of trial NCT01059227?
This trial is currently completed. The enrollment target is 39 participants. The study started on 2010-01-22. Estimated completion is 2015-08-14.
Who is sponsoring clinical trial NCT01059227?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI